A multicenter, observational, retrospective study of infliximab biosimilar in pediatric-onset inflammatory bowel disease
Latest Information Update: 20 Sep 2022
At a glance
- Drugs Infliximab (Primary) ; Infliximab (Primary) ; Infliximab (Primary) ; Infliximab (Primary)
- Indications Crohn's disease; Inflammatory bowel diseases; Ulcerative colitis
- Focus Adverse reactions; Therapeutic Use
- 01 Oct 2022 Results published in the European Journal of Gastroenterology and Hepatology
- 20 Sep 2022 New trial record